Breast Cancer

Systemic lupus erythematosus is a risk factor for increased mortality in elderly patients with early breast cancer, according to data published in Arthritis Care & Research.

The addition of ribociclib to front-line letrozole prolonged OS among postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer, results of the randomized phase 3 MONALEESA-2 trial showed.

Genetic testing for hereditary cancer should be offered to all women aged older than 65 years with triple-negative or ER-negative breast cancer, according to study results published in Journal of Clinical Oncology.

Reducing disparities in cancer care requires an understanding of “the science of trustworthiness” and a greater focus on social determinants of health, according to a leader in health equity research.

Medication can play an essential role in breast cancer prevention, Holly J. Pederson, MD, director of medical breast services at the Cleveland Clinic, said during the NAMS Annual Meeting.

Genomic testing has afforded today’s patient the advantage of knowing when they harbor a potentially dangerous genetic mutation, such as BRCA1 or BRCA2.

The FDA granted breakthrough therapy designation to trastuzumab deruxtecan for second-line treatment of patients with metastatic HER2-positive breast cancer.

A comprehensive approach to screening for breast cancer and working with patients to reduce their lifestyle risks can save more lives, Lisa Larkin, MD, FACP, NCMP, IF, said during the NAMS Annual Meeting.

The American Association for Cancer Research named Graham A. Colditz, MD, DrPH, MPH, the recipient of this year’s AACR Distinguished Lectureship on the Science of Cancer Health Disparities.

Women with early breast cancer who were treated with the novel anti-hormonal therapy giredestrant saw reductions in tumor activity before surgery, according to interim data presented at the European Society for Medical Oncology Congress.